as 07-26-2024 4:00pm EST
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
Founded: | 2008 | Country: | United Kingdom |
Employees: | N/A | City: | ABINGDON, OXFORDSHIRE |
Market Cap: | 212.5M | IPO Year: | 2015 |
Target Price: | $4.29 | AVG Volume (30 days): | 1.7M |
Analyst Decision: | Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.66 | EPS Growth: | N/A |
52 Week Low/High: | $0.42 - $2.05 | Next Earning Date: | 08-07-2024 |
Revenue: | $18,358,000 | Revenue Growth: | -74.21% |
Revenue Growth (this year): | 4.87% | Revenue Growth (next year): | -24.42% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Piccina Cintia | ADAP | Chief Commercial Officer | Jun 18 '24 | Sell | $0.93 | 24,531 | $22,813.83 | 38,293 | SEC Form 4 |
Rawcliffe Adrian | ADAP | Chief Executive Officer | Jan 16 '24 | Sell | $0.79 | 9,304 | $7,350.16 | 14,104 | SEC Form 4 |
Rawcliffe Adrian | ADAP | Chief Executive Officer | Jan 16 '24 | Sell | $0.67 | 30,080 | $20,243.84 | 44,848 | SEC Form 4 |
Lunger John | ADAP | Chief Patient Supply Officer | Jan 16 '24 | Sell | $0.79 | 4,681 | $3,697.99 | 7,023 | SEC Form 4 |
Lunger John | ADAP | Chief Patient Supply Officer | Jan 16 '24 | Sell | $0.67 | 5,309 | $3,572.96 | 7,785 | SEC Form 4 |
Lunger John | ADAP | Chief Patient Supply Officer | Jan 16 '24 | Sell | $0.67 | 12,805 | $8,617.77 | 19,015 | SEC Form 4 |
Bertrand William C JR | ADAP | Chief Operating Officer | Jan 16 '24 | Sell | $0.79 | 4,681 | $3,697.99 | 7,023 | SEC Form 4 |
Bertrand William C JR | ADAP | Chief Operating Officer | Jan 16 '24 | Sell | $0.67 | 5,309 | $3,572.96 | 7,785 | SEC Form 4 |
Bertrand William C JR | ADAP | Chief Operating Officer | Jan 16 '24 | Sell | $0.67 | 13,599 | $9,152.13 | 20,201 | SEC Form 4 |
Norry Elliot | ADAP | Chief Medical Officer | Jan 11 '24 | Sell | $0.85 | 7,799 | $6,661.13 | 11,841 | SEC Form 4 |
Norry Elliot | ADAP | Chief Medical Officer | Jan 11 '24 | Sell | $0.84 | 4,009 | $3,354.33 | 6,104 | SEC Form 4 |
Bertrand William C JR | ADAP | Chief Operating Officer | Jan 11 '24 | Sell | $0.84 | 4,009 | $3,354.33 | 6,104 | SEC Form 4 |
Bertrand William C JR | ADAP | Chief Operating Officer | Jan 11 '24 | Sell | $0.85 | 5,220 | $4,458.40 | 7,874 | SEC Form 4 |
Rawcliffe Adrian | ADAP | Chief Executive Officer | Jan 11 '24 | Sell | $0.84 | 11,945 | $9,994.38 | 18,395 | SEC Form 4 |
Rawcliffe Adrian | ADAP | Chief Executive Officer | Jan 11 '24 | Sell | $0.85 | 17,257 | $14,739.20 | 26,388 | SEC Form 4 |
Lunger John | ADAP | Chief Patient Supply Officer | Jan 11 '24 | Sell | $0.84 | 4,009 | $3,354.33 | 6,104 | SEC Form 4 |
Lunger John | ADAP | Chief Patient Supply Officer | Jan 11 '24 | Sell | $0.85 | 5,220 | $4,458.40 | 7,874 | SEC Form 4 |
ADAP Breaking Stock News: Dive into ADAP Ticker-Specific Updates for Smart Investing
Insider Monkey
2 days ago
BioPharma Dive
24 days ago
Zacks Small Cap Research
24 days ago
Zacks Small Cap Research
a month ago
Yahoo Finance Video
2 months ago
GlobeNewswire
2 months ago
Reuters
2 months ago
USA TODAY
2 months ago
The information presented on this page, "ADAP Adaptimmune Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.